Literature DB >> 3033751

Quality of life of inoperable non-small cell lung carcinoma. A randomized phase II clinical study comparing radiotherapy alone and combined radio-chemotherapy.

P Minet, P Bartsch, P Chevalier, D Raets, A Gras, M T Dejardin-Closon, G Lennes.   

Abstract

Eighty one patients with inoperable non-small cell lung carcinoma (NSCLC) were entered in a randomized phase II trial comparing split-dose irradiation alone to combined treatment radiotherapy and polychemotherapy (C.A.P. + V.D.S.). The quality of life and the survival of the patients were studied. We have defined three classes of quality of life responses based on the time elapsed before the performance status index drops. A higher quality of life failure rate was observed in the combined treatment group (p non-significant) but the time elapsed before the Karnofsky index drops is longer in the combined treatment group for the quality of life "no change" subgroup (p = 0.15). Survival and quality adjusted survival are similar in both treatment groups. The same conclusion holds for retrospective stratified treatment groups. The results of the study are presented according to the decision tree theory. We conclude that as far as the quality of life is concerned, polychemotherapy combined with the particular split-dose irradiation schedule used is an effective treatment of inoperable NSCLC. Its efficiency is comparable to, but not better than, the same radiotherapy schedule alone taken as a reference baseline.

Entities:  

Mesh:

Year:  1987        PMID: 3033751     DOI: 10.1016/s0167-8140(87)80245-1

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

Review 1.  Quality of life measurement for patients undergoing treatment for lung cancer.

Authors:  R J Fergusson; A Cull
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

2.  Monitoring changes in quality of life in patients with lung cancer by using specialised questionnaires: implications for clinical practice.

Authors:  Hellie Lithoxopoulou; Konstantinos Zarogoulidis; Sevasti Bostantzopoulou; Ellada Eleftheriadou; Paul Zarogoulidis; Haidong Huang; Konstantinos Porpodis; Ioannis Kioumis; Theodora Tsiouda; Lonny Yarmus; Theodore Kontakiotis
Journal:  Support Care Cancer       Date:  2014-03-22       Impact factor: 3.603

3.  Women with lung cancer: impact on quality of life.

Authors:  L Sarna
Journal:  Qual Life Res       Date:  1993-02       Impact factor: 4.147

4.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

Authors: 
Journal:  BMJ       Date:  1995-10-07

5.  Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer.

Authors:  J B Sørensen; B Bergman; A L Nielsen; M Krarup; P Dombernowsky; H H Hansen
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.